3P Biopharmaceuticals among the 500 fastest growing companies in Spain

This is the first year the company appears in the ranking established by CEPYME for 500 companies that lead business growth in Spain.

3P Biopharmaceuticals (3P), a leading contract development and manufacturing organization (CDMO) specializing in the process development and cGMP manufacturing of biological products is now one of the 11 companies from Navarra that appear in the ranking of the 500 companies that lead business growth in Spain according to the ranking established by CEPYME.

The CEPYME500 ranking is based on the evaluation of a set of indicators that measure the growth, solvency, innovation potential and international projection of these companies. The main function of this initiative is to give national and international recognition and projection to the companies that have been selected, thus improving their growth potential and visibility.

To select the 500 most relevant companies in the Spanish economy, financial variables and indicators of innovation and international expansion have been combined. This exhaustive analysis has been possible thanks to the collaboration of Informa D&B, the leader in business and business information, which manages a database with highly qualified commercial and financial information.
The biotechnology company located in Noáin has 350 employees and has a turnover projection for this year that confirms the continuous annual growth. Since its beginnings in 2007, the company has already added 60 clients, almost all of which are international and located in 20 countries.

3P Biopharmaceuticals among the 500 fastest growing companies in Spain

With respect to its facilities, the company has a global investment plan of 45 million euros, which began in 2020 and will continue until 2025.
Dámaso Molero, CEO of 3P Biopharmaceuticals states: ” We could not have finished this year better. We are very proud to receive this recognition from Cepyme. The history of 3P has been like climbing mountains and the mountain always surprises you. It is the same with biotechnology. Our achievements and our growth in these 15 years have been achieved thanks to the great work done every day by the professionals who make up 3P.”

For 3P Biopharmaceuticals, this recognition complements the one it received last September from Actualidad Económica, in which it was selected as one of the 100 best companies to work for in Spain.

View the full press release here

Our dedicated team of specialists will be happy to discuss any of your CDMO supply chain needs. Contact us on +34 948 346 480 or email withinus@3pbio.com

Related Content

3P Biopharmaceuticals continues its successful collaboration with Toleranzia AB to fight Myasthenia Gravis.

Published: 19th September 2023
Toleranzia is at the forefront of innovation with their groundbreaking candidate, TOL2, designed to address the autoimmune neuromuscular disease, Myasthenia Gravis (MG).
Read more

3P Biopharmaceuticals lands in the United States.

Published: 8th June 2023
The Navarre biological CDMO inaugurates its first commercial office in Boston, supported by Keensight Capital.
Read more

3P Biopharmaceuticals continues its collaboration with U.S. biotech Zhittya for the treatment of Parkinson’s disease.

Published: 2nd May 2023
The process transfer and GMP supply of the FGF-1 candidate have been achieved successfully by both companies.
Read more

Get in touch

Let’s discuss your biologics journey.

Discover more about our people, our passion, and how we can work together to improve lives.